Abingdon Health announces formation of Scientific & Medical Advisory Board. Appointment of Dr. Chris Hand, Professor Donal Bradley and Professor Mark Drayson.

14 September 2015

Abingdon Health Ltd, is pleased to announce the formation of a Scientific & Medical Advisory Board ("the SMA Board"). The SMA Board will provide independent, expert advice, scrutiny and oversight of the Group’s R&D and product implementation activities. The SMA Board will be multi-disciplinary and its members will provide expertise in the areas considered to be important for the Abingdon Health’s future scientific development. The contribution of the SMAB will be a vital component of Abingdon Health’s strategic planning process.

The initial appointees to the Scientific & Medical Advisory Board will be Dr. Chris Hand, current Chairman of Abingdon Health, Professor Donal D.C. Bradley CBE, FRS, CEng, FIET, FInstP, FRSA and Professor Mark Drayson, MBChB, PhD, FRCPath. Dr. Chris Hand will be Chairman of the Scientific & Medical Advisory Board.

Professor Donal D.C. Bradley CBE, FRS, CEng, FIET, FInstP, FRSA
Professor Donal Bradley is Head of the Mathematical, Physical and Life Sciences (MPLS) Division and Professor of Engineering Science and Physics at the University of Oxford.

Previously Professor Bradley was Vice-Provost (Research), Director of the Centre for Plastic Electronics, and Lee-Lucas Professor of Experimental Physics at Imperial College London. As VP(R) he championed a wide range of cross-faculty research initiatives, including a coordinated translation and impact acceleration programme, and led the successful launch of a pan-College PhD scholarships programme. He also provided pump-priming funding for a variety of new programmes in, for example, Data Science and Engineering, Medical Diagnostics and Advanced Functional Materials, and he oversaw the formation of 12 Imperial-led EPSRC Centres for Doctoral Training.

Professor Bradley’s personal research interests focus on plastic electronics – encompassing fundamental studies on low-temperature/solution processed semiconductor materials and their application in a range of fields including energy efficient displays, lighting and solar panels; sensing and imaging devices; and photonic components for communications. He is a co-inventor of conjugated polymer electroluminescence and a co-founder of Cambridge Display Technology Ltd and Molecular Vision Ltd. He is also a Director of Solar Press (UK) Ltd. Professor Bradley has more than 25 patent families to his name, and is ranked in the top 1% of most highly cited materials science researchers in the world. His research has been recognised by numerous awards and prizes including the IET and IOP Faraday Medals, the Royal Society Bakerian Lecture and the EU Descartes Prize. He was appointed a CBE in 2010 for services to science.

Professor Mark Drayson, MBChB, PhD, FRCPath
Professor Drayson is Professor of Clinical Immunodiagnostics, College of Medical and Dental Sciences, University of Birmingham. He is Director of the Clinical Immunology Service ("CIS"), Birmingham and an Honorary Consultant at University Hospitals Birmingham and Heart of England. Professor Drayson has directed the CIS since 2000. The service provides a unique interface between the University’s substantial scientific expertise in immunology and the clinical investigation and management of blood cancers, immunodeficiency and autoimmunity in the West Midlands. Providing 500,000 immunodiagnostic tests per year for a population of five million, the CIS is in an ideal position for research and development. He provides central laboratory analysis for UK clinical trials in myeloma and is chief investigator for two. The results of these trials are helping formulate world opinion on investigation and management of the disease. He has played a key role developing and demonstrating the utility of tests for serum immunoglobulin free light chains in myeloma, other B-cell dyscrasias and related conditions.

Rapid Diagnostic Technologies
Professor Drayson has developed a second generation of the test (‘Seralite®’) which is a rapid test based on monoclonal antibodies. This is being commercialised by Abingdon Health Ltd, providing improved laboratory and unique near-patient versions of the test. He is a member of national and international guidelines groups for diagnosis and management of myeloma and MGUS. His basic research in blood cancers is finding new therapies for blood cancers by drug redeployment which he is testing in trials in the UK and Africa. He has major grants from Cancer Research UK, Leukaemia Lymphoma Research, Medical Research Council and National Institute of Health Research.

Commenting on the announcement, Dr. Chris Hand, said:

“I am pleased to announce the formation of the Scientific & Medical Advisory Board and the appointments of Professor Donal Bradley and Professor Mark Drayson.

I am delighted to be working with such pre-eminent scientists who will play an important role in guiding Abingdon Health’s development programmes and building and developing the Group’s strategy.”

Enquiries:
Abingdon Health Ltd  +44 121 414 5166
Dr. Chris Hand, Chairman
Chris Yates, CEO

Notes to editors

About Abingdon Health – www.abingdonhealth.com

Abingdon Health Ltd is a UK based in vitro diagnostic group focused on developing a range of rapid testing products in the area of hematology oncology. The Company launched its first rapid testing product in March 2015, Seralite® – FLC, the world’s first rapid diagnostic device in multiple myeloma, and is in the process of launching a range of complementary rapid tests.

The Company’s core expertise lies in the development, manufacturing and commercialisation of rapid lateral flow immunoassay diagnostics and reader systems. To support its strategic plan Abingdon is currently developing a multiplexed immunoassay rapid testing system based on fully disposable medical diagnostics for the rapid testing market. This device uses organic light emitting diodes (OLEDs) and organic photodetectors (OPDs) for versatile and quantitative optical detection in a portable and disposable format.